On August 25, Moderna, Inc. rose 3.99% in pre-market trading, trading at $144.22/share, with turnover of $8.12 million. The stock remains in a volatile price discovery phase following the historic 177% single-day surge triggered by its mRNA cancer vaccine Phase III trial success.

The movement reflects ongoing re-rating momentum after Moderna and Merck announced that their personalized mRNA cancer vaccine intismeran autogene met the primary endpoint in the Phase III INTerpath-001 melanoma trial, marking the first positive randomized Phase III result for an mRNA cancer therapy. The stock has experienced extreme swings — a 177% surge, a 23.5% pullback, and a 16% rebound — as Wall Street recalibrates valuations. Multiple banks have raised price targets, including BofA to $170, Jefferies to $150, Barclays to $125, and Goldman Sachs to $120, though consensus remains at hold. Options implied volatility sits at the 99.6th percentile, reflecting continued uncertainty around fair value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)